Given Imaging (NASDAQ: GIVN) and C R Bard (NYSE:BCR) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, valuation, earnings, risk, analyst recommendations and profitability.

Valuation and Earnings

How to Become a New Pot Stock Millionaire

This table compares Given Imaging and C R Bard’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Given Imaging N/A N/A N/A N/A N/A
C R Bard $3.71 billion 6.50 $531.40 million $7.59 43.64

C R Bard has higher revenue and earnings than Given Imaging.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Given Imaging and C R Bard, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Given Imaging 0 0 0 0 N/A
C R Bard 0 7 0 0 2.00

C R Bard has a consensus price target of $310.60, suggesting a potential downside of 6.23%.

Profitability

This table compares Given Imaging and C R Bard’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Given Imaging N/A N/A N/A
C R Bard 9.51% 19.39% 6.91%

Institutional and Insider Ownership

79.1% of C R Bard shares are owned by institutional investors. 0.8% of C R Bard shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Dividends

C R Bard pays an annual dividend of $0.78 per share and has a dividend yield of 0.2%. Given Imaging does not pay a dividend. C R Bard pays out 10.3% of its earnings in the form of a dividend. Given Imaging has increased its dividend for 46 consecutive years.

Summary

C R Bard beats Given Imaging on 7 of the 9 factors compared between the two stocks.

Given Imaging Company Profile

Given Imaging Ltd (Given) develops, manufactures and markets diagnostic products for the visualization and detection of disorders of the gastrointestinal tract. It is engaged in capsule endoscopy, which is an approach to visual examination of the gastrointestinal tract through the use of a miniaturized video camera contained in an ingestible disposable capsule. Its principal product, which incorporates its core technology, is the Given System, a wireless imaging system that uses its disposable video capsules, the PillCam capsules. The PillCam capsules can be easily ingested by patients and move naturally through the gastrointestinal tract while wirelessly transmitting to a portable recorder, enabling the gastroenterologist to view video, images and data on a computer workstation, utilizing its RAPID software. In October 2012, it acquired the assets related to the SmartPill GI Monitoring System from The SmartPill Corporation.

C R Bard Company Profile

C. R. Bard, Inc. (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis. Its vascular products cover a range of minimally invasive devices for the treatment of peripheral vascular disease and end-stage renal disease. Its urology products include basic urology drainage products, fecal and urinary continence products, urological specialty products and Targeted Temperature Management products. Its oncology products cover a range of devices used in the treatment and management of various cancers, and other diseases and disorders. Its surgical specialty products include implanted patches and fixation devices for hernia and soft tissue repairs.

Receive News & Ratings for Given Imaging Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Given Imaging and related companies with MarketBeat.com's FREE daily email newsletter.